Graves' disease (GD) is an autoimmune thyroid disease in which stimulation by thyrotropin-receptor antibodies (TRAb) causes thyroid enlargement and hyperfunction. GD is an uncommon condition during gestation, as it occurs in about 0.2% of pregnant women. The typical GD course during gestation is characterized by a progressive reduction of TRAb levels, with associated clinical improvement, but subsequent recurrence after delivery. Instead, gestational GD requires close monitoring, because if inadequately controlled with maternal TRAb levels remaining elevated, it is associated with adverse maternal, fetal, and neonatal outcomes. We describe the case of a 39-year-old woman, who was diagnosed with stress-triggered GD at 1st trimester of her pregnancy. At diagnosis, TRAb levels were very high (30.4 U/L, normal values < 1.5). Five weeks after antithyroid drug (ATD) was started, hyperthyroidism returned, coinciding with an increase of TRAb levels (> 40 U/L). Three additional exacerbations of hyperthyroidism occurred at weeks 28 (TRAb > 40 U/L), 32 (TRAb 36.4 U/L), and 36 (TRAb 26.2 U/L), despite close biochemical monitoring and adjustments of ATD. An uncomplicated spontaneous delivery of a healthy boy occurred at week 37. The neonate had normal weight, length, Apgar score, and was euthyroid (TSH 1.9 mIU/mL). He remained healthy and euthyroid at the last evaluation (9 months of age). This case is unusual because of several exacerbations of GD hyperthyroidism while on ATD during gestation, due to persistently high TRAb levels. Nevertheless, thanks to close maternal and fetal monitoring, neither maternal nor fetal complication occurred.
Introduction
Thyroid hyperfunction affects 0.1 to 0.5% of pregnancies [1, 2] , the leading etiology in this setting being Graves' disease (GD) accounting for 85% of the cases [3] .
GD is an autoimmune thyroid disease caused by thyrotropin (TSH)-receptor antibodies (TRAb) with stimulating activity on the thyrocyte growth and function [3] . Physical, psychological, or other type of stress may precipitate the onset of hyperthyroidism, its exacerbation while on antithyroid drugs (ATD) and relapse after withdrawal of ATD [4] [5] [6] [7] . Particularly, pregnancy and delivery are two physical and psychological stressful conditions that were reported to precede GD hyperthyroidism in predisposed women [5] [6] [7] . Typically, GD exacerbates in the first trimester but improves thereafter [2] . This course is due to the gestational immunological tolerance producing a decrease in thyroid antibodies levels, including TRAb, and a subsequent clinical improvement of GD after the first trimester.
This tolerance is lost after delivery, thus explaining the postpartum recurrence of hyperthyroidism [1, 8, 9] .
An optimal management of GD throughout pregnancy is very important because, if inadequately controlled, it is associated with adverse maternal, fetal, and neonatal outcomes, including eclampsia, maternal congestive heart failure, miscarriage, preterm delivery, intrauterine growth restriction, congenital malformations, low birth weight, and fetal thyroid dysfunctions including thyroid storm and even fetal death [9, 10] .
We report here a woman in whom stress-induced GD onset occurred during the first trimester, and unusually exacerbated thereafter, despite continuous treatment with ATD and close maternal and fetal monitoring. Although TRAb levels were persistently high throughout pregnancy, she gave birth to a euthyroid, healthy boy at week 37. As hyperthyroidism exacerbated also during the postpartum period, she underwent thyroidectomy 8 months after delivery.
Case Report
A 39-year-old nonsmoking Caucasian woman with no past history of thyroid disease was admitted for suspected hyperthyroidism to our Endocrinology Unit at the 11th gestational week (GW). About 3 months before her referral, she started to complain of tremors, weight loss, heat intolerance, and fatigue. This symptomatology followed a period of overwork.
At physical examination, resting tachycardia, hyperreflexia, warm and moist skin, diffuse goiter, and absence of ophthalmopathy were apparent. Confirming the clinical diagnosis, laboratory investigations showed overt hyperthyroidism (TSH = 0.001 mU/L [normal values 0.27-4.2], FT4 = 69.4 pmol/L [normal values [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , FT3 = 42.2 pmol/L [normal values 3.1-6.8]). Thyroglobulin antibodies (TgAb) and thyroperoxidase autoantibodies (TPOAb) tested negative, and TRAb levels were high (30.4 U/L, normal values < 1.5). Neck ultrasound showed a goiter (22 mL) with markedly hypoechoic and grossly inhomogeneous and pseudonodular echotexiture. Parenchymal vascularization was markedly increased.
Thus, GD was diagnosed and ATD was prescribed. As per the 2017 American Thyroid Association guidelines [11] , propylthiouracil (PTU) was preferred over methimazole (MMI) [12] , and the starting daily dose was 200 mg. The clinical and biochemical follow-up during gestation was on a weekly basis, and it is summarized in Fig. 1 . Not to complicate the figure, not shown is the weekly biochemical monitoring for hematologic and hepatic side effects of ATD. Complete blood count and liver chemistry panel were normal (except for a modest raise in gamma-glutamyl transferase and alkaline phosphatase levels between the 16th and the 17th GW) until a few weeks before delivery (see below). After 3 weeks and a progressive reduction of PTU dose to 50 mg/die, serum FT4 and FT3 fell in the upper normal range, matching the amelioration of the symptomatology complained by the patient.
At GW 15, namely 5 weeks after the therapy had been started, the hyperthyroidism symptomatology exacerbated, coinciding with an increase of serum FT4, FT3, and TRAb levels (> 40 UI/L). Indeed, she was very scared of the potential harmful consequences on the fetus of uncontrolled hyperthyroidism. Being on the second trimester of gestation, as per guidelines [11] , PTU was switched to MMI, at the daily dose of 10 mg. We proposed elective surgery to be performed at the end of the second trimester, but the patient refused it. Two weeks later (GW 18), FT4 was normal (17.7 pmol/L), FT3 was high (8.9 pmol/L), and TRAb persistently high (> 40 UI/ L). At the 20th GW, the daily dose of MMI was increased to 15 mg; concomitantly, considering the high TRAb levels, close fetal monitoring was started. Fetal ultrasound revealed no signs of either thyrotoxicosis or hypothyroidism (heart rate 142 beat per minute, normal body growth, normal bone maturation, no goiter, normal movements, and amniotic fluid volume). At the 23rd GW, the patient reported a very stressful period for the illness and sudden death of her father. Two additional fetal US performed at 31st and 35th GW confirmed the absence of signs of either thyrotoxicosis or hypothyroidism. At week 24, the oral glucose tolerance test revealed gestational diabetes (plasma glucose 5.4 mmol/L at 0 min, 7.2 mmol/L at 60 min, 5.2 mmol/L at 120 min), which required diet and insulin therapy consisting in daily injection of glargine from GW 28.
Later on, three further exacerbations of hyperthyroidism oc- , and viral hepatitis markers were negative. Consequently, the hepatologist prescribed ursodeoxycholic acid at 450 mg/day, with gradual improvement of itching over the following weeks. At the 36th GW, modest bilateral eyelid retraction appeared.
One day before the 38th GW, an uncomplicated labor occurred, and a healthy boy was spontaneously delivered in another hospital. The neonate had normal weight (2.890 g), length (47.5 cm), head circumference (34 cm), and Apgar score (10 points at 1 and 5 min after birth), and was euthyroid (TSH 1.9 mU/L). TRAb levels were not measured, but they were undetectable at 1 month of age. At 1 week, the breast-fed child weighed 2.700 g and had no suction problems and no signs of hyperthyroidism. At the last evaluation, 9 months after birth, the boy had normal growth, was clinically and biochemically euthyroid (TSH 3.35 mU/L) with undetectable TgAb, TPOAb, and TRAb. At ultrasonography, thyroid was normally sized (~1 mL) and not hypervascularized.
At week 3 postpartum, while under MMI 10 mg/day, she complained of dysphagia, asthenia, and tremors. Heart rate was 88 bpm, there were tremors, and goiter was visibly more enlarged. Indeed, ultrasonography showed a doubling volume of the thyroid (44 mL), which contained three subcentimetric nodules. Laboratory tests revealed hyperthyroidism (suppressed TSH, FT4 = 44.4 pmol/L, FT3 = 19.8 pmol/L, TRAb = 29.6 UI/L). We strongly recommended thyroidectomy but the patient decided to postpone it, preferring to continue MMI and monthly follow-up.
Total thyroidectomy was performed at the 8th month postpartum. The day before thyroid surgery, she was slightly overtreated (suppressed TSH, FT4 11.30 pmol/L, calcitriol, these analytes gradually normalized over the next days, permitting to stop calcium and calcitriol supplementation. Levothyroxine replacement was also started after thyroidectomy. At the last visit (week 8 post-surgery), TSH was 0.9 mU/L and TRAb were decreased but still high (12.8 U/L), while on 775 μg/week levothyroxine.
Discussion
GD onset or recurrence(s) may typically occur either in the first trimester of pregnancy or in the postpartum period, especially during the first year [13] . Maternal and fetal adverse outcomes are directly related to a poor control of thyrotoxicosis, consisting in elevated thyroid hormones and TRAb levels. Particularly, exposure to excessive levels of thyroid hormones during pregnancy can lead to maternal hypertension, preeclampsia, thyroid storm, congestive heart failure, pregnancy loss, prematurity, intrauterine growth restriction, and stillbirth [14] . Nevertheless, both TRAb and ATD cross the placenta affecting the fetal thyroid. As ATD is more potent in the fetus than in the mother, fetal hypothyroidism may occur in the face of maternal euthyroidism [14] . Therefore, pregnant women with GD requiring ATD should be treated with the smallest possible dose whenever is possible [11] . Typically, due to the gestational immunological tolerance, a significant number of women can withdraw ATD in the last trimester of pregnancy, but once this tolerance is lost after delivery, the risk of relapse of GD is high [15, 16] .
In the case here reported, GD was diagnosed in the late first trimester, when hyperthyroidism was clinically and biochemically evident, but it likely began either in early pregnancy or just before conception. Although ATD was promptly administered and the woman was closely monitored both clinically and biochemically, four exacerbation occurred throughout pregnancy (Fig. 1) . Although we could not assess rigorously the patient's compliance by pill count at visit, we felt confident of her good compliance since her husband, who accompanied her at each visit, took care of her throughout the pregnancy and provided her with ATD tablets every day. Furthermore, the patient had no mental disease potentially affecting her compliance to ATD therapy. Worthy of note, the onset and one exacerbation were preceded by two major psychological stressful events, namely overwork over the weeks prior to pregnancy and the death of her father, respectively. She was also concerned about the consequences of hyperthyroidism on the fetus throughout the pregnancy. The mechanisms whereby physical, psychological, and infectious stressful events trigger the onset and the recurrences of hyperthyroidism in GD patients are still unknown. Stress-induced activation of the hypothalamus-pituitary-adrenal axis resulting in increase of cortisol secretion but decrease of dehydroepiandrosterone secretion may affect the immune system. Particularly, the imbalance of T lymphocyte classes induced by the activation of the hypothalamus-pituitary-adrenal axis has been proposed [4] . Also, the intensity of stress is directly correlated with the severity of the ensuing hyperthyroidism [4, 17] .
In stress-triggered GD [7] , but more generally in GD, serum T3 and FT3 tend to be disproportionately elevated more than T4 and FT4, resulting in the so-called "T3-toxicosis" [11, 18] . Therefore, high T3 to T4 ratio can distinguish thyrotoxicosis caused by GD from thyrotoxicosis by destructive processes [2, 11] . In the case presented here, FT3 levels were relatively more increased compared with FT4 levels at onset. Interestingly, FT3 remained above the upper normal limit through the pregnancy, as opposed to FT4, which was kept within the reference range except for exacerbations. Also, at each exacerbation, FT3 peaked relatively higher compared with FT4 ( Fig. 1) .
Another key point of our case was the persistently high levels of TRAb during pregnancy and the postpartum period. In the first trimester, TRAb measurement is important for either diagnosing GD in women presenting with thyrotoxicosis or for deciding whether to stop ATD in those already taking these drugs from before conception [11] . As TRAb cross the placental barrier (see above), they can stimulate the fetal thyroid leading to hyperthyroidism, which typically develops at week 20 or later [14] . Ultrasonographic signs of fetal hyperthyroidism include tachycardia (> 160 bpm for > 10 min), intrauterine growth retardation, fetal hydrops, centrally hypervascularized goiter, and accelerated bone maturation (with evident distal femoral ossification core before 32 weeks) [19] . Serum TRAb > 5 U/L, which is about three times the upper normal limit for the assay, predict fetal and neonatal hyperthyroidism [20, 21] . In our case, despite maternal high TRAb levels, the fetus did not show ultrasonographic signs of either hyperthyroidism or hypothyroidism, and the neonate was euthyroid at birth and later on. Indeed, switching of the functional properties of TRAb from stimulating to neutral or blocking was reported [22] . Signs of neonatal hyperthyroidism become apparent only from 2 to 5 days after birth, which is the time necessary for ATD to be cleared, but can be delayed up to some weeks if stimulating antibodies coexist with blocking ones [23] . Concerning the case here presented, as TRAb were assayed by an immunoassay, no inference could be made on the biological activity of them. However, as expected, these antibodies decreased in the third trimester due to the pregnancy-related immunosuppression/hemodilution [21] . TRAb levels persisted at high levels also during the postpartum period, and further exacerbation of hyperthyroidism occurred 3 weeks after delivery. In contrast, women who have withdrawn ATD before pregnancy or in the late pregnancy experience a relapse of GD generally between the 4th and 8th month after delivery [21] .
Very recently, we have demonstrated that increased parenchymal vascularization and a markedly hypoechogenic ultrasonographic pattern are correlated positively with TRAb levels in untreated GD patients, and in turn, TRAb levels at onset are higher in patients that will experience recurrence(s) of hyperthyroidism [24] . Particularly, those with TRAb levels at least 5-fold over the upper normal limit show more intense vascularization [24] . In the woman reported here, neck ultrasound at onset of hyperthyroidism showed a goiter with markedly hypoechoic and grossly and pseudonodular echopattern. Also, TRAb levels were > 30 U/L during almost all duration of pregnancy. All these ultrasonographic and biochemical features, along with the young age, rendered her more likely to have recurrence(s).
As our patient refused to undergo thyroidectomy in the second trimester [11, 25] , and hyperthyroidism persisted after delivery, together with dysphagia and a significant increase of thyroid volume compared with the first trimester, thyroidectomy was favored over radioiodine and was performed at month 8 postpartum. Early severe postoperative hypocalcemia ensued, according to the reported higher rates of symptomatic hypocalcemia after thyroidectomy for GD compared with that performed for other reasons. Increased bone hunger due to thyrotoxic osteodystrophy and a more demanding surgical procedure resulting in higher risk of parathyroid injury have been proposed [26] .
At the last visit (2 months post-thyroidectomy), TRAb were still positive and at high levels (12.8 U/L). In a prospective randomized study, the decrease over time of TRAb levels was evaluated in GD patients treated with ATD, thyroidectomy, and radioiodine therapy [27] . Whereas in those treated either with ATD or thyroidectomy, TRAb decreased gradually and disappeared in about 75% of patients after 18 months, in those who underwent radioiodine therapy, TRAb first peaked at 3 months but then decreased gradually and disappeared in about 60% after 5 years [27] . TRAb kinetics have to be kept in mind in women who are willing to have another pregnancy after either thyroid surgery or radiodine therapy. In line with this evidence [21, 27] , we advised the patient to plan future pregnancy after normalization of TRAb levels.
The case reported here reminds that GD can have an unpredictable course during pregnancy and postpartum. Therefore, a close maternal and fetal/neonatal biochemical and ultrasonographic monitoring and cooperation between endocrinologist, gynecologist, and neonatologist are of the utmost importance in order to prevent maternal and fetal adverse outcomes.
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